Defense Production Act (DPA) Title III Request for Information (RFI) on Advanced Canopy Transparencies In an effort to fortify the defense industrial base and enhance the reliability of critical aviation components, the U.S. Air Force Research Laboratory (AFRL) has issued a Request for Information (RFI) under Title III of the Defense Production Act (DPA). This […]
DPA Title III RFI on Advanced Canopy Transparencies Read More »
ASPR Industrial Base Management and Supply Chain Request for Information (RFI) Understanding the RFI The Public Health Industrial Base Capabilities and Capacities: Essential Medicines RFI is seeking detailed input from domestic manufacturers and industry stakeholders to better understand the current capabilities and constraints in producing a list of 28 designated essential medicines. The scope includes
ASPR RFI: Public Health Industrial Base Capabilities and Capacities: Essential Medicines Read More »
Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining Available Vaccines and Envisioning Novelty (RAVEN). This RFI reflects DTRA’s responsibility to prepare the U.S. warfighter for current and emerging
DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation Read More »
Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is
A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an era marked by evolving biological agents and unpredictable infectious threats. The DoD is particularly interested in repurposed FDA-approved therapeutics or
DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats Read More »
Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic
Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »
Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays
Key Takeaways from the April 2025 Executive Order On April 2, 2025, President Trump issued an Executive Order titled “Modernizing Defense Acquisitions and Spurring Innovation in the Defense Industrial Base.” This directive signals a major shift in how the Department of Defense (DoD) acquires technology, emphasizing speed, flexibility, and inclusion of non-traditional contractors. 1. Streamlining
April 2025 Executive Order Read More »
NSCEB Final Report: Charting the Future of Biotechnology in America The National Security Commission on Emerging Biotechnology (NSCEB) has released its final report, “Charting the Future of Biotechnology: An Action Plan for American Security and Prosperity.” This document outlines a strategic roadmap emphasizing the need for the United States to significantly increase investment—recommending a minimum
Charting the Future of Biotechnology Read More »
Strengthening America’s Defense: The Defense Innovation Unit’s Blue Manufacturing Initiative In an era where rapid technological advancement is crucial for national security, the Defense Innovation Unit (DIU) has launched the Blue Manufacturing Initiative. This strategic program aims tobolster the United States defense manufacturing capabilities by fostering partnerships with trustedadvanced manufacturing companies. Addressing Critical Challenges The
DIU Launches Blue Manufacturing Marketplace Read More »
The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies
Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »
DARPA_PS_25-05_R3_ERIS_Announcement_1_Feb_2025_ (3) Overview The Defense Advanced Research Projects Agency (DARPA) is the U.S. Department of Defense’s premier agency for driving technological innovation and funding breakthrough capabilities to ensure national security. Known for pioneering technologies like the internet and GPS, DARPA focuses on high-risk, high-reward research that can lead to the development of critical strategic products.
DARPA’s ERIS Marketplace Read More »
